Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 1, 2016 (10 years ago)

CEFTRIAXONE for Injection USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

CGMP Deviations: Out of specification (OOS) intermediate in the subsequent processes to manufacture the final API.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

CEFTRIAXONE for Injection USP, 250mg/vial, Rx only, MFG: LUPIN LIMITED INDIA, Packaged by Aidarex Pharmaceuticals, NDC 53217-0117-01

Affected NDC 53217-0117-01

Compare with the code on your package — it is the most precise check available.

Drug: Ceftriaxone

Recalling firm
Aidarex Pharmaceuticals LLC
NDC code
53217-0117-01
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0974-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ceftriaxone recalls

See all

Other recalls by Aidarex Pharmaceuticals LLC

All 2016 recalls
Class III · Low risk

Enalapril Maleate

Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.

Terminated Impurity / degradation Aidarex Pharmaceuticals LLC D-0992-2018
Class III · Low risk

Enalapril Maleate

Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.

Terminated Impurity / degradation Aidarex Pharmaceuticals LLC D-0991-2018
Class III · Low risk

Enalapril Maleate

Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.

Terminated Impurity / degradation Aidarex Pharmaceuticals LLC D-0990-2018